Evidence map›Paper›PMID 31940362›Full record

ArticlePloS one2020

Structural variation and its potential impact on genome instability: Novel discoveries in the EGFR landscape by long-read sequencing.

George W Cook, Michael G Benton, Wallace Akerley, George F Mayhew, Cynthia Moehlenkamp, Denise Raterman, Daniel L Burgess, William J Rowell, Christine Lambert, Kevin Eng and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Effect of theFrontiers in endocrinology · 2023
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The epigenetic basis of cellular heterogeneity.Nature reviews. Genetics · 2021
    Review
  17. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.International journal of molecular sciences · 2021
    Review
  18. Article
  19. Review
  20. MicroRNAs Regulating Autophagy in Neurodegeneration.Advances in experimental medicine and biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

George W CookSentry Genomics, Baton Rouge, LA, United States of America.ORCID 0000-0001-6413-8680
Michael G BentonDepartment of Chemical Engineering, Louisiana State University, Baton Rouge, LA, United States of America.
Wallace AkerleyHuntsman Cancer Institute, University of Utah School of Medicine, Department of Oncological Sciences, Salt Lake City, UT, United States of America.
George F MayhewRoche Sequencing Solutions, Madison, WI, United States of America.ORCID 0000-0003-0609-6018
Cynthia MoehlenkampRoche Sequencing Solutions, Madison, WI, United States of America.
Denise RatermanRoche Sequencing Solutions, Madison, WI, United States of America.ORCID 0000-0002-2161-5245
Daniel L BurgessRoche Sequencing Solutions, Madison, WI, United States of America.ORCID 0000-0001-8566-7100
William J RowellPacific Biosciences, Menlo Park, CA, United States of America.ORCID 0000-0002-7422-1194
Christine LambertPacific Biosciences, Menlo Park, CA, United States of America.
Kevin EngPacific Biosciences, Menlo Park, CA, United States of America.ORCID 0000-0002-7076-5397
Jenny GuPacific Biosciences, Menlo Park, CA, United States of America.
Primo BaybayanPacific Biosciences, Menlo Park, CA, United States of America.
John T FussellSentry Genomics, Baton Rouge, LA, United States of America.
Heath D HerboldSentry Genomics, Baton Rouge, LA, United States of America.
John M O'SheaHuntsman Cancer Institute, Biorepository Molecular Pathology, Salt Lake City, UT, United States of America.ORCID 0000-0002-8063-7436
Thomas K VargheseHuntsman Cancer Institute, University of Utah School of Medicine, Department of Surgery, Division of Thoracic Surgery, Salt Lake City, UT, United States of America.
Lyska L EmersonHuntsman Cancer Institute, University of Utah School of Medicine, Department of Pathology, Salt Lake City, UT, United States of America.ORCID 0000-0002-2367-6578
Pacific Biosciences (United States) · USUniversity of Utah · USHuntsman Cancer Institute · USLouisiana State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Structural variation (SV) is typically defined as variation within the human genome that exceeds 50 base pairs (bp). SV may be copy number neutral or it may involve duplications, deletions, and complex rearrangements. Recent studies have shown SV to be associated with many human diseases. However, studies of SV have been challenging due to technological constraints. With the advent of third generation (long-read) sequencing technology, exploration of longer stretches of DNA not easily examined previously has been made possible. In the present study, we utilized third generation (long-read) sequencing techniques to examine SV in the EGFR landscape of four haplotypes derived from two human samples. We analyzed the EGFR gene and its landscape (+/- 500,000 base pairs) using this approach and were able to identify a region of non-coding DNA with over 90% similarity to the most common activating EGFR mutation in non-small cell lung cancer. Based on previously published Alu-element genome instability algorithms, we propose a molecular mechanism to explain how this non-coding region of DNA may be interacting with and impacting the stability of the EGFR gene and potentially generating this cancer-driver gene. By these techniques, we were also able to identify previously hidden structural variation in the four haplotypes and in the human reference genome (hg38). We applied previously published algorithms to compare the relative stabilities of these five different EGFR gene landscape haplotypes to estimate their relative potentials to generate the EGFR exon 19, 15 bp canonical deletion. To our knowledge, the present study is the first to use the differences in genomic architecture between targeted cancer-linked phased haplotypes to estimate their relative potentials to form a common cancer-linked driver mutation.

Indexed as

Genetic VariationGenomic InstabilityHigh-Throughput Nucleotide SequencingCarcinoma, Non-Small-Cell LungComputer SimulationGenes, erbB-1Genome, HumanHaplotypesHumansLung NeoplasmsSequence Analysis, DNA

Identifiers

PMID31940362
PMCPMC6961855
OpenAlexW2999639651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.